The invention relates to a decoquinate nanoemulsion coccidium-resisting drug. The particle size of the decoquinate nanoemulsion coccidium-resisting drug is 1-100nm, the decoquinate nanoemulsion coccidium-resisting drug consists of, by mass percentage, decoquinate 0.1-6.0%, surface active agent 20.0-35.0%, cosurfactant 0-22.0%, cosolvent 1.0-3.0%, oil 1.5-12.0% and the balance distilled water. The drug is light yellow, is clear and transparent liquid visually, has the advantages of being good in stability, low in viscosity, strong in dispersibility, rapid in absorption and the like, and further has slow releasing and targeting effects. The bioavailability of the drug can be improved, half-life period of the drug in the body can be prolonged, and curative effect is enhanced. The decoquinate nanoemulsion coccidium-resisting drug is simple in preparation process, low in energy consumption, small in toxicity and high in safety, and can be produced in a mass mode without requiring special equipment.